share_log

Heart Test Laboratories | 424B3: Prospectus

Heart Test Laboratories | 424B3: Prospectus

Heart Test Laboratories | 424B3:募資說明書
SEC announcement ·  03/18 18:09
牛牛AI助理已提取核心訊息
Heart Test Laboratories, Inc. (HeartSciences) has filed a prospectus with the SEC for the resale of up to 34,684,859 shares of common stock by selling stockholders. The shares include 4,854,853 shares issued to Icahn School of Medicine at Mount Sinai (Mount Sinai) and additional shares issuable upon exercise of warrants. The company is also registering shares that may be sold to Lincoln Park Capital Fund, LLC (Lincoln Park) under a purchase agreement. HeartSciences will not receive proceeds from the selling stockholders, except from any cash exercise of warrants. Proceeds from sales to Lincoln Park will be used for working capital and general corporate purposes. The company's common stock and warrants are listed on the Nasdaq Capital Market under the symbols 'HSCS' and 'HSCSW,' respectively. The filing includes provisions that may deter hostile takeovers or changes in control or management.
Heart Test Laboratories, Inc. (HeartSciences) has filed a prospectus with the SEC for the resale of up to 34,684,859 shares of common stock by selling stockholders. The shares include 4,854,853 shares issued to Icahn School of Medicine at Mount Sinai (Mount Sinai) and additional shares issuable upon exercise of warrants. The company is also registering shares that may be sold to Lincoln Park Capital Fund, LLC (Lincoln Park) under a purchase agreement. HeartSciences will not receive proceeds from the selling stockholders, except from any cash exercise of warrants. Proceeds from sales to Lincoln Park will be used for working capital and general corporate purposes. The company's common stock and warrants are listed on the Nasdaq Capital Market under the symbols 'HSCS' and 'HSCSW,' respectively. The filing includes provisions that may deter hostile takeovers or changes in control or management.
心臟測試實驗室有限公司(HeartSciences)已向美國證券交易委員會提交了招股說明書,要求通過出售股東轉售多達34,684,859股普通股。這些股票包括向西奈山(西奈山)伊坎醫學院發行的4,854,853股股票,以及行使認股權證後可發行的額外股票。該公司還註冊了可能根據購買協議出售給林肯公園資本基金有限責任公司(林肯公園)的股份。HeartSciences不會從出售股東那裏獲得收益,除非從認股權證的現金行使中獲得收益。向林肯公園出售的收益將用於營運資金和一般公司用途。該公司的普通股和認股權證分別在納斯達克資本市場上市,代碼分別爲 “HSCS” 和 “HSCSW”。該文件包括可能阻止敵對收購或控制權或管理變更的條款。
心臟測試實驗室有限公司(HeartSciences)已向美國證券交易委員會提交了招股說明書,要求通過出售股東轉售多達34,684,859股普通股。這些股票包括向西奈山(西奈山)伊坎醫學院發行的4,854,853股股票,以及行使認股權證後可發行的額外股票。該公司還註冊了可能根據購買協議出售給林肯公園資本基金有限責任公司(林肯公園)的股份。HeartSciences不會從出售股東那裏獲得收益,除非從認股權證的現金行使中獲得收益。向林肯公園出售的收益將用於營運資金和一般公司用途。該公司的普通股和認股權證分別在納斯達克資本市場上市,代碼分別爲 “HSCS” 和 “HSCSW”。該文件包括可能阻止敵對收購或控制權或管理變更的條款。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。